This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.
https://ift.tt/2PEh40e
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: Available online 22 March 2017 Source: Medical Journal Armed Forces India Author(s): S.C. Shaw, M.S. Vinod, Amit Devgan ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου